AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Transplantation ConditioningTransplantation, HomologousHematopoietic Stem Cell TransplantationBusulfanBone Marrow TransplantationConditioning, ClassicalGraft vs Host DiseaseTransplantation, AutologousWhole-Body IrradiationLiver TransplantationConditioning (Psychology)Myeloablative AgonistsVidarabineTransplantation ChimeraGraft SurvivalKidney TransplantationHematologic NeoplasmsStem Cell TransplantationConditioning, EyelidCyclophosphamideImmunosuppressive AgentsTreatment OutcomeTissue DonorsMelphalanAntilymphocyte SerumCord Blood Stem Cell TransplantationHistocompatibility TestingHeart TransplantationGraft RejectionLung TransplantationPeripheral Blood Stem Cell TransplantationRecurrenceAnemia, AplasticHistocompatibilityCombined Modality TherapyFearSurvival AnalysisRetrospective StudiesLeukemiaChimerismDisease-Free SurvivalOrgan TransplantationAntineoplastic Combined Chemotherapy ProtocolsGraft vs Tumor EffectRemission InductionTime FactorsHepatic Veno-Occlusive DiseaseTransplantation, IsogeneicHemibody IrradiationSurvival RateConditioning, OperantPancreas TransplantationMyelodysplastic SyndromesIslets of Langerhans TransplantationCyclosporineLiving DonorsTransplantation ImmunologyTransplantationMultiple MyelomaLymphocyte DepletionImmunosuppressionCell TransplantationFollow-Up StudiesAntineoplastic Agents, AlkylatingLymphoma, Non-HodgkinAcute DiseaseLeukemia, Myeloid, AcuteEtoposideHLA AntigensCytarabineThiotepaSalvage TherapyUnrelated DonorsInfectionHematologic DiseasesCarmustineAssociation LearningBlinkingIdarubicinPrecursor Cell Lymphoblastic Leukemia-LymphomaSevere Combined ImmunodeficiencyStomatitisHematopoietic Stem Cell MobilizationElectroshockAnemia, Refractory, with Excess of BlastsMucositisSiblingsTransplantation, HeterotopicHodgkin DiseaseFreezing Reaction, CatalepticTransplantation ToleranceHeart-Lung TransplantationPrognosisBone Marrow PurgingAutograftsT-LymphocytesLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRisk FactorsLymphatic Irradiation
Hematopoietic cellPost transplantationMarrow transplantationDonorHSCTChemotherapy regimenHematologicTherapy and autologous stem cell transFollowed by autologous stem cell transOutcomesToxicitiesGVHDAutologous hematopoieticUmbilical cord blood tranTransplantsCyclophosphamideMultiple myelomaAcuteHaploidenticalMyeloablative conditiTotal body irradiBlood stem cell transplantEtoposideStem cellFludarabineBone marrowNonmyeloablativeClinicalBEAMRenalSurvivalReceiving alloHCTPreparativeImmuneToxicityLymphoma
Hematopoietic cell20
  • Although allogeneic hematopoietic cell transplantation (alloHCT) is the treatment of choice, patient eligibility criteria and optimal conditioning regimen remain under study. (confex.com)
  • A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. (stembook.org)
  • Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. (bvsalud.org)
  • An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. (bvsalud.org)
  • 2,732 nasal wash samples collected during the fi rst year gesting that these viruses might not cause respiratory ill- after allogeneic hematopoietic cell transplantation from 222 ness in immunocompetent children. (cdc.gov)
  • Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. (stembook.org)
  • Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. (stembook.org)
  • Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. (stembook.org)
  • Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. (stembook.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. (mdanderson.org)
  • Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. (mdanderson.org)
  • We aimed to study the outcome of hematopoietic cell transplantation (HCT) in patients with DADA2. (cardiff.ac.uk)
  • Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation. (stjude.org)
  • Since beginning the BMCF in 1992, Christina has dedicated her life to improving the quality of life for cancer patients and bone marrow/Hematopoietic Cell Transplantation (HCT) transplant patients and their families. (bonemarrow.org)
  • Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Central venous catheter placement is required before the administration of hematopoietic cell transplantation. (medscape.com)
Post transplantation8
  • Donor/sponsor chimerism was regularly performed every 3 months for the 1st yr post transplantation using short-tandem repeat (STR) amplified by polymerase chain reaction (PCR). (bio-cavagnou.info)
  • Life-threatening infections required vasopressors and/or intubation and included Sobetirome any viral end-organ disease EBV-post-transplantation lymphoproliferative disorder (EBV-PTLD) or infections. (bio-cavagnou.info)
  • Post-transplantation maintenance therapy with low-dose lenalidomide yields improved PFS and overall survival (OS). (medscape.com)
  • At post transplantation day plus 3, antibiotic drug therapy was switched from piperacillin/tazobactam to meropenem. (cdc.gov)
  • The main efficacy outcome measures were time to neutrophil recovery following transplantation and the incidence of Blood and Marrow Transplant Clinical Trials Network Grade 2/3 bacterial or Grade 3 fungal infections through Day 100 post transplantation. (fda.gov)
  • The incidence of Blood and Marrow Transplant Clinical Trials Network Grade 2/3 bacterial or Grade 3 fungal infections through Day 100 post transplantation was 39% and 60%, respectively, in the two groups. (fda.gov)
  • After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival. (knowcancer.com)
  • Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. (mcw.edu)
Marrow transplantation15
Donor14
  • Since 2013, we have introduced FluTreo for patients with a suitable donor that would have been previously eligible only for reduced intensity conditioning/RIC. (confex.com)
  • In autologous transplantation, the donor and recipient is the same individual. (medscape.com)
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. (ox.ac.uk)
  • In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation. (ox.ac.uk)
  • A second apheresis or a bone marrow collection was considered, but neither was performed because the clinical condition of the donor worsened. (cdc.gov)
  • To determine whether antigen-specific immunity, induced in the stem cell donor, can be passively transferred to the allogeneic SCT recipient in the setting of a non-myeloablative conditioning regimen. (drugpatentwatch.com)
  • Overview and choice of donor of hematopoietic stem cell transplantation. (mayoclinic.org)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • When used in mice, this antibody resulted in excellent donor stem cell take and cured mice that had a condition equivalent to human SCID. (ca.gov)
  • In order for donor stem cells to grow in the patient's bone marrow, the patient's bone marrow cells have to be eliminated by a pre-treatment known as conditioning. (swisshealthmagazine.ch)
  • Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades. (mcw.edu)
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
HSCT9
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemia remains a challenge. (nih.gov)
  • The Spring School was an educational event aimed at providing in-depth knowledge and understanding of hematopoietic stem cell transplantation (HSCT) for immune dysregulation and immunodeficiency disorders. (ebmt.org)
  • The meeting commenced with a presentation on the fundamental principles of Hematopoietic Stem Cell Transplantation (HSCT) for Immunodeficiency, followed by a thorough discussion of the indications for HSCT. (ebmt.org)
  • The meeting featured a presentation on selecting an appropriate conditioning regimen and bridging strategies to HSCT. (ebmt.org)
  • This remains an important indication for hematopoietic stem cell transplantation (HSCT). (swisshealthmagazine.ch)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
Chemotherapy regimen4
  • 1 , 2 Owing to this complication, clinical studies have increasingly focused on AHCT as consolidative therapy, with particular examination of the optimal conditioning chemotherapy regimen. (jamanetwork.com)
  • Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) as part of a standardized chemotherapy regimen. (wikipedia.org)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • To determine the efficacy of a novel conventional chemotherapy regimen (Fludarabine-EPOCH) in the setting multiple myeloma. (drugpatentwatch.com)
Hematologic6
  • Statistical Analysis This study was designed as a single center non-randomized phase II trial to investigate the feasibility and security of a non-myeloablative conditioning routine plus an unmodified peripheral blood stem cell transplant in individuals with hematologic malignancies who are not candidates for myeloablative conditioning by virtue of age prior organ toxicity or intensity of prior therapy. (bio-cavagnou.info)
  • On April 17, 2023, the FDA approved omidubicel-onlv, brand name Omisirge, for use in adult and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. (fda.gov)
  • Safety and efficacy were evaluated in Study P0501, an open-label, multicenter, randomized trial of omidubicel-onlv transplantation or unmanipulated cord blood unit transplantation following myeloablative conditioning in patients with hematologic malignancies. (fda.gov)
  • Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies. (knowcancer.com)
  • New stem cell transplantation research conducted by physicians at selected stem cell transplant centers and at Miami Cancer Institute , part of Baptist Health, is showing promise in the fight against relapse, a leading cause of death in patients with hematologic cancers. (broadcastmed.net)
  • Among the most revolutionary therapies for hematologic malignancies is stem cell transplantation, which had its beginnings in the 1950s. (broadcastmed.net)
Therapy and autologous stem cell trans1
Followed by autologous stem cell trans2
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. (umassmed.edu)
Outcomes4
Toxicities2
  • In most cases comorbid conditions contributed to these toxicities. (nature.com)
  • We also provide a brief review of the toxicities associated with these regimens. (bvsalud.org)
GVHD5
  • Reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT) have used alemtuzumab to abrogate the risk of graft-versus-host disease (GVHD). (bio-cavagnou.info)
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • GVHD has been reported after syngeneic and autologous transplantation but is rare. (medscape.com)
  • We observed groups of metabolites associated with CMV infection, but also to related clinical factors including graft-versus-host disease (GvHD) and the pre-transplantation conditioning regimen. (mdpi.com)
  • No recognizable alteration in supportive care, conditioning regimen, GVHD prophylaxis or cytokine usage was associated with this striking increase in the frequency of DAH after allografting. (nih.gov)
Autologous hematopoietic2
Umbilical cord blood tran2
  • It is intended for use in patients with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen, such as radiation or chemotherapy. (bioprocessintl.com)
  • Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen. (lu.se)
Transplants1
  • The conditioning regimens for the final transplants were myeloablative (n = 20), reduced intensity (n = 8), or non-myeloablative (n = 2). (cardiff.ac.uk)
Cyclophosphamide1
Multiple myeloma4
Acute1
Haploidentical3
  • 70 years, ECOG performance status≥3 at presentation, induction regimens≤2, and autologous or haploidentical HCT because these were performed in individual patients. (confex.com)
  • The three main categories of allogeneic transplantation are HLA identical, HLA mismatched, and haploidentical. (medscape.com)
  • Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. (mdanderson.org)
Myeloablative conditi2
  • We have previously shown an advantage of a myeloablative conditioning regimen with reduced toxicity (Fludarabine 150mg/m 2 , Treosulfan 42g/m 2 , FluTreo) compared to a reduced intensity regimen. (confex.com)
  • Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation. (ox.ac.uk)
Total body irradi2
  • Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. (nature.com)
  • Multiple conditioning regimens were used, including Total Body Irradiation-based or chemotherapy-based options. (fda.gov)
Blood stem cell transplant2
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
Etoposide3
  • Early efforts used the well-established conditioning regimen of carmustine, etoposide, cytarabine and melphalan (BEAM), and more recent trials have used thiotepa-based conditioning, either alone or in comparison with BEAM, owing to thiotepa's superior CNS penetration, because components of the BEAM regimen do not effectively cross the blood-brain barrier. (jamanetwork.com)
  • All patients received high-dose etoposide (60 mg/kg) and allogeneic stem cell transplantation following the TBI. (nature.com)
  • In a phase II trial reported in JAMA Oncology , Locke J. Bryan, MD , and colleagues found that the combination of pembrolizumab with ICE chemotherapy (a regimen including ifosfamide, carboplatin, and etoposide) produced a high rate of complete response in patients with relapsed or refractory classical Hodgkin lymphoma who were candidates for autologous stem cell transplantation (SCT). (ascopost.com)
Stem cell23
Fludarabine1
  • Recipient conditioning consisted of 20 mg CAMPATH-1H on days -8 to -4, 30 mg/m(2) fludarabine on days -7 to -3, and 140 mg/m(2) melphalan on day -2. (ox.ac.uk)
Bone marrow1
Nonmyeloablative2
  • In this article, we provide a review of the definition of high- dose , reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. (bvsalud.org)
  • A nonmyeloablative conditioning regimen was investigated in 47 patients with hematological malignancy receiving allogeneic progenitor cells from matched, unrelated donors. (ox.ac.uk)
Clinical3
  • Dual antiviral therapy improved the clinical condition and reduced the viral load. (frontiersin.org)
  • We have brought together world experts in transplantation, protein development and clinical study design who have the shared objective of bringing the technology of antibody targeting stem cells to patients. (ca.gov)
  • In a clinical investigation, 17 patients with Hairy Cell Leukemia and normal renal function were treated for 7 days with the recommended treatment regimen of LEUSTATIN Injection (0.09 mg/kg/day) by continuous intravenous infusion. (nih.gov)
BEAM2
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • CONCLUSIONS: Conditioning with CBV or BEAM and subsequent ASCT was feasible and effective. (smw.ch)
Renal1
Survival1
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
Receiving alloHCT1
  • However, the long-term effects of this regimen remain unknown, especially in comparison to patients not receiving alloHCT. (confex.com)
Preparative1
  • However, as the contribution of graft -versus- tumor effects to the success of allogeneic HCT was recognized over time , in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. (bvsalud.org)
Immune1
  • Myeloablative conditioning is recommended to prevent rejection caused by residual immune function. (frontiersin.org)
Toxicity3
  • 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m 2 (8.2% vs 14.7%, NS). (nature.com)
  • Determine the toxicity of this regimen in these patients. (knowcancer.com)
  • however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. (nih.gov)
Lymphoma3
  • Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma? (jamanetwork.com)
  • The investigators concluded, "Results suggest that the addition of pembrolizumab to ICE chemotherapy was well tolerated and highly effective in comparison with prior reports of chemotherapy-only regimens, supporting further investigation in patients with relapsed or refractory classic[al] Hodgkin lymphoma eligible for an autologous SCT. (ascopost.com)
  • They point out that previous cases of pulmonary and disseminated nocardiosis have been associated with alemtuzumab treatment, but only in patients with preexisting conditions that compromise immunity, including non- Hodgkin's lymphoma, B cell lymphocytic leukemia, and organ transplantation. (medscape.com)